XOMA Royalty Corp
ersodetug
congenital HI
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on ersodetug for congenital HI is in focus around Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“Rezolute will meet with FDA under its Breakthrough Therapy Designation in the first quarter of 2026 to determine next steps for the program”